title: HDACi: molecular mechanisms and therapeutic implications in the innate immune system.
abstract: Histone deacetylase inhibitors (HDACi) are an emerging class of novel anti-cancer drugs that cause growth arrest, differentiation and apoptosis of tumor cells. In addition, many advances have been made in understanding the immunoregulation of Toll-like receptors, NOD-like receptors and interferons that have recently generated new momentum for the study of HDACi in immunity as a whole, and in the regulation of these innate signaling pathways specifically. HDACi have shown promise as new anti-inflammatory and immunosuppressant agents. They have also demonstrated great potency and relative selectivity in various human/animal models of inflammatory diseases. This review focuses on recent progress and the current state of HDACi knowledge, as well as the molecular mechanisms and therapeutic potential of HDACi for the treatment of inflammatory diseases and cancers.
authors.affiliation: College of Applied Medical Sciences, Taibah University, Al-Madinah Al-Munawwarah, Saudi Arabia.
authors.forename: Bandar Ali
authors.initials: BA
authors.lastname: Suliman
authors.forename: Dakang
authors.initials: D
authors.lastname: Xu
authors.forename: Bryan R G
authors.initials: BR
authors.lastname: Williams
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D056572:Histone Deacetylase Inhibitors / Q000627:therapeutic use*; D006801:Humans; D007107:Immune System / Q000187:drug effects* / Q000276:immunology; D007113:Immunity, Innate / Q000187:drug effects* / Q000276:immunology; D007155:Immunologic Factors / Q000627:therapeutic use*; D018448:Models, Immunological
chemical_list: D000893:Anti-Inflammatory Agents; D000970:Antineoplastic Agents; D056572:Histone Deacetylase Inhibitors; D007155:Immunologic Factors